Identification of discrepancy between CTLA4 expression and CTLA4 activation in gastric cancer

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. PubMed PMID: 26808342; eng.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. PubMed PMID: 25651787; eng.
   PubMed Web of Science ®Google Scholar
• Price TJ, Shapiro JD, Segelov E, et al. Management of advanced gastric cancer [Review]. Expert Rev Gastroenterol Hepatol. 2012;6:199. quiz 209. PubMed PMID: 22375525; eng.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial]. N Engl J Med. 2010;363:711–723. PubMed PMID: 20525992; PubMed Central PMCID: PMC3549297. eng.
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis [Meta-Analysis Review]. BMC Med. 2015;13:211. PubMed PMID: 26337719; PubMed Central PMCID: PMC4559965. eng.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:e180013. PubMed PMID: 29543932; PubMed Central PMCID: PMC5885175. eng.
   PubMed Web of Science ®Google Scholar
• Joshi SS, Maron SB, Catenacci DV. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol. 2018;14:417–430. PubMed PMID: 29094609; PubMed Central PMCID: PMC5827797. eng.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Sanchez-Vega F, Jonsson P, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018;8:49–58. PubMed PMID: 29122777; PubMed Central PMCID: PMC5813492. eng.
   PubMed Web of Science ®Google Scholar
• Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase ii trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16:1662–1672. PubMed PMID: ISI:000278545500034; English.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–211. PubMed PMID: ISI:000362405600039; English.
   PubMed Web of Science ®Google Scholar
• Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab [Clinical Trial, Phase II Multicenter Study Randomized Controlled Trial]. Cancer Immunol Immunother. 2012;61:1019–1031. PubMed PMID: 22146893; eng.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Lin Y, Lin HM, et al. Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. Oncoimmunology. 2017;6:e1231291. PubMed PMID: 28344862; PubMed Central PMCID: PMC5353928. eng.
   PubMed Web of Science ®Google Scholar
• Yee NS. Update in systemic and targeted therapies in gastrointestinal oncology [Congresses]. Biomedicines. 2018;6:34. PubMed PMID: 29547556; PubMed Central PMCID: PMC5874691. eng.
   Web of Science ®Google Scholar
• Cao B, Wang Q, Zhang H, et al. Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma. Oncoimmunology. 2018;7:e1392427. PubMed PMID: 29308323; PubMed Central PMCID: PMC5749623. eng.
   PubMed Web of Science ®Google Scholar
• Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209. PubMed PMID: ISI:000341362800044; English.
   PubMed Web of Science ®Google Scholar
• Kang BW, Seo AN, Yoon S, et al. Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer [Research Support, Non-U.S. Gov't]. Ann Oncol. 2016;27:494–501. PubMed PMID: 26673353; Eng.
   PubMed Web of Science ®Google Scholar
• Grogg KL, Lohse CM, Pankratz VS, et al. Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol. 2003;16:641–651. PubMed PMID: 12861059; eng.
   PubMed Web of Science ®Google Scholar
• Chiaravalli AM, Feltri M, Bertolini V, et al. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch. 2006;448:344–353. PubMed PMID: 16261379; Eng.
   PubMed Web of Science ®Google Scholar
• Ge S, Xia X, Ding C, et al. A proteomic landscape of diffuse-type gastric cancer [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Nat Commun. 2018;9:1012.PubMed PMID: 29520031; PubMed Central PMCID: PMC5843664. eng.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes [Research Support, Non-U.S. Gov't]. Nat Med. 2015;21:449–456. PubMed PMID: 25894828; eng.
   PubMed Web of Science ®Google Scholar
• Cui JA, Li F, Wang GQ, et al. Gene-expression signatures can distinguish gastric cancer grades and stages. Plos One. 2011;6:e17819. PubMed PMID: ISI:000288545100033; English.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ni Z, Duan Z, et al. Overexpression of E2F mRNAs associated with gastric cancer progression identified by the transcription factor and miRNA co-regulatory network analysis [Research Support, Non-U.S. Gov’t]. Plos One. 2015;10:e0116979. PubMed PMID: 25646628; PubMed Central PMCID: PMC4315469. Eng.
   PubMed Web of Science ®Google Scholar
• Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol. 2012;189:1123–1127.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Zhou ZJ, Xia GK, et al. A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. Oncogene. 2017;36:5122–5133. PubMed PMID: 28481874; eng.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–15550. PubMed PMID: 16199517; PubMed Central PMCID: PMC1239896. Eng.
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. BMC Bioinformatics. 2013;14:7. PubMed PMID: 23323831; PubMed Central PMCID: PMC3618321. eng.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer [Research Support, Non-U.S. Gov't]. Immunity. 2013;39:782–795. PubMed PMID: 24138885; eng.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? [Review]. BMC Med. 2016;14:73. PubMed PMID: 27151159; PubMed Central PMCID: PMC4858828. eng.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. combined nivolumab and ipilimumab or monotherapy in untreated melanoma [clinical trial, phase iii comparative study randomized controlled trial research support, Non-U.S. Gov't]. N Engl J Med. 2015;373:23–34. PubMed PMID: 26027431; eng.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't]. Clin Cancer Res. 2010;16:1042. PubMed PMID: 20086001; eng.
   PubMed Web of Science ®Google Scholar
• Gullo I, Carvalho J, Martins D, et al. The transcriptomic landscape of gastric cancer: insights into Epstein-Barr virus infected and microsatellite unstable tumors. IJMS. 2018;19:2079. pii: E2079. PubMed PMID: 30018250; eng.
   Google Scholar
• Zhao X, Subramanian S. Intrinsic resistance of solid tumors to immune checkpoint blockade therapy [review research support, Non-U.S. Cancer Res. 2017;77:817–822. PubMed PMID: 28159861; eng.
   PubMed Web of Science ®Google Scholar
• Lonberg N, Korman AJ. Masterful antibodies: checkpoint blockade [review]. Cancer Immunol Res. 2017;5:275–281. PubMed PMID: 28373215; eng.
   PubMed Web of Science ®Google Scholar
• Park C, Cho J, Lee J, et al. Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. Oncoimmunology. 2017;6:e1356150. PubMed PMID: 29147610; PubMed Central PMCID: PMC5674954. eng.
   PubMed Web of Science ®Google Scholar
• Zhao B, Zhang X, Krummenacher C, et al. Immunization with Fc-based recombinant Epstein-Barr virus gp350 elicits potent neutralizing humoral immune response in a BALB/c mice model. Front Immunol. 2018;9:932. PubMed PMID: 29765376; PubMed Central PMCID: PMC5938345. eng.
   PubMed Web of Science ®Google Scholar
• Tunger A, Kiessler M, Wehner R, et al. Immune monitoring of cancer patients prior to and during CTLA-4 or PD-1/PD-L1 inhibitor treatment [review]. Biomedicines. 2018;6:26. PubMed PMID: 29494517; PubMed Central PMCID: PMC5874683. eng.
   Web of Science ®Google Scholar
• Chen PL, Roh W, Reuben A, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827–837. PubMed PMID: 27301722; Eng.
   PubMed Web of Science ®Google Scholar
• Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma [Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't]. J Transl Med. 2011;9:204. PubMed PMID: 22123319; PubMed Central PMCID: PMC3239318. eng.
   PubMed Web of Science ®Google Scholar
• Xing X, Guo J, Wen X, et al. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology. 2018;7:e1356144. PubMed PMID: 29399387; PubMed Central PMCID: PMC5790386. eng.
   PubMed Web of Science ®Google Scholar
• Yu Y. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. Front Med. 2018;12:229–235.
   PubMed Web of Science ®Google Scholar
• Kuzushima K, Nakamura S, Nakamura T, et al. Increased frequency of antigen-specific CD8(+) cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma [Case Reports Research Support, Non-U.S. J Clin Invest. 1999;104:163–171. PubMed PMID: 10411545; PubMed Central PMCID: PMC408473. eng.
   PubMed Web of Science ®Google Scholar
• Inoue H, Park JH, Kiyotani K, et al. Intratumoral expression levels of PD-L1, GZMA and HLA_A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunenology. 2016;5:e1204507.
   PubMed Web of Science ®Google Scholar